spacer
home > ebr > autumn 2018 > editors letter
PUBLICATIONS
European Biopharmaceutical Review

Editors Letter

Fewer than 10 advanced therapy medicinal products (ATMPs) are currently licensed for use in Europe. The R&D pipeline of early stage ATMP candidates is strong at present, but the manifold challenges (including chemistry, manufacturing and controls, clinical trials, and complex regulatory pathways) to bringing these potentially transformational therapies to market are such that it will take considerable time before their full potential in healthcare is realised. In this autumn 2018 edition of EBR, The Christie Hospital’s Dr Fiona Thistlethwaite and Aptus Clinical’s Dr Ian Thomas introduce the Innovate UK-funded iMatch consortium of clinical and commercial researchers, who will aim to overcome some of the key barriers to successful progression of ATMPs and their scale-up for a range of chronic debilitating conditions (page 14). A major therapeutic focus of ATMP development is oncology, spearheaded by the recently approved Kymriah, for acute B-cell lymphoblastic lymphoma, and Yescarta, for non-Hodgkin lymphoma, from Novartis and Kite/ Gilead respectively. These classes of drug are one of the precision therapies included in N-of-One’s Dr Kathryn D Bungartz’s comprehensive summary of the current cancer therapy innovation landscape (page 56). So too are antibody-drug conjugates, the challenges in production of which and the potential means to circumvent are discussed by the Sanofi and Merck Group teams (page 80).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemeras preservative-free multidose eye dropper Novelia® approved for Santens Cosopt® for Glaucoma treatments in 29 European countries

Nemera is pleased to announce that its multidose eye dropper Novelia® has been approved for the preservative-free formulation Cosopt iMulti® (20mg/ml dorzolamide + 5mg/ml timolol eye drops, solution).
More info >>

White Papers

Technology Solutions - Driving efficiencies, quality and operational excellence

Worldwide Clinical Trials Ltd

Clinical trials involve the entry, analysis and reporting of millions of pieces of data; year-on-year, the amount of data required to manage efficacy and safety increases exponentially. Recently, solutions available to support this activity have grown in numbers and complexity. The rise of Tablets and Smart Phones combined with the growth of Cloud or SAS solutions has resulted in the technology landscape required to support complex, global studies becoming more confusing.
More info >>

 
Industry Events

Respiratory Drug Delivery (RDD®) Europe 2019

7-10 May 2019, Estoril Congress Center, Lisbon

Respiratory Drug Delivery (RDD®) Europe 2019 connects emerging and high-level scientists, academics, industrial and regulatory specialists, and clinicians. It is a must-attend conference for companies involved in research, development, testing or marketing of medicines, devices and services associated with pulmonary or nasal pharmaceutical products. This year, RDD Europe 2019 will be held in Estoril (Lisbon), Portugal, May 7-10, 2019, and, as in previous years is jointly organized by RDD Online and Aptar Pharma.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement